Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Arvinas Inc.'s peak revenue was $263.4M in 2024. The peak quarterly revenue was $102.4M in 2024(q3).
Arvinas Inc.'s revenue increased from $7.6m in 2017 to $263.4M currently. That's a 3,375.45% change in annual revenue.
| Fiscal year / year | Arvinas Inc. revenue |
|---|---|
| 2017 | $7.6M |
| 2018 | $14.3M |
| 2019 | $43.0M |
| 2020 | $25.9M |
| 2021 | $53.6M |
| 2022 | $131.4M |
| 2023 | $78.5M |
| 2024 | $263.4M |
Rate Arvinas Inc.'s financial transparency
Arvinas Inc. saw the greatest revenue growth in 2019, when revenue increased by 200.2%.
Arvinas Inc. had the lowest revenue growth in 2020, when revenue changed by -39.77%.
| Year | Arvinas Inc. growth |
|---|---|
| 2018 | 89%↑ |
| 2019 | 200%↑ |
| 2020 | -40%↓ |
| 2021 | 107%↑ |
| 2022 | 145%↑ |
| 2023 | -40%↓ |
| 2024 | 236%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | $3.4M | $3.4M |
| 2019 | $4.0M | $4.0M | $30.1M | $4.9M |
| 2020 | $6.2M | $5.7M | $7.6M | $6.3M |
| 2021 | $5.5M | $5.5M | $9.3M | $33.2M |
| 2022 | $26.5M | $33.8M | $33.2M | $37.8M |
| 2023 | $32.5M | $54.5M | $34.6M | ($43.1M) |
| 2024 | $25.3M | $76.5M | $102.4M | $59.2M |
Do you work at Arvinas Inc.?
Did Arvinas Inc. meet its revenue projections?
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 83 |
| Date Founded | 2013 |
| Headquarters | New Haven, Connecticut |
| Number of Locations | 1 |
| Revenue | $263.4M |
| Net Income | -$282,500,000 |
| Tax Rate | -0.0% |
| Total Assets | $1,268,800,000 |
| Ticker | ARVN |
Arvinas Inc. received early financing of $15.0M on 2013-09-26.
| Series | Round size | Date |
|---|---|---|
| Series A | $15M | 09/2013 |
| Series B | $41.6M | 10/2015 |
| Series C | $55M | 04/2018 |
| Investors | Security type |
|---|---|
| Elm Street Ventures | Series A |
| Canaan | Series A |
| Connecticut Innovations | Series A |
| 5 Am Ventures | Series A |
| Canaan | Series B |
| 5 Am Ventures | Series B |
| OrbiMed Advisors | Series B |
| RA Capital Management | Series B |
| New Leaf Venture Partners | Series B |
| Canaan | Series C |
| Sirona Capital | Series C |
| Deerfield | Series C |
| 5 Am Ventures | Series C |
| Nextech Invest | Series C |
| Hillhouse Capital Group | Series C |
| OrbiMed Advisors | Series C |
| RA Capital Management | Series C |
| New Leaf Venture Partners | Series C |
Arvinas Inc.'s top competitor, Rigel Pharmaceuticals, earned an annual revenue of $179.3M.
Arvinas Inc.'s smallest competitor is Shattuck Labs with revenue of $543.8K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Centrose | - | $370,000 | 3 | - |
| Applied Molecular Transport | - | $8.3M | 80 | - |
| Allakos | - | $15.6M | 125 | - |
| Molecular Templates | - | $38.7M | 261 | - |
| Cara Therapeutics | - | $7.1M | 84 | - |
| Cognition Therapeutics | - | $19.5M | 30 | - |
| C4 Therapeutics | - | $35.6M | 300 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| Rigel Pharmaceuticals | - | $179.3M | 158 | - |
| Nurix | - | $54.5M | 103 | - |
Zippia gives an in-depth look into the details of Arvinas Inc., including salaries, political affiliations, employee data, and more, in order to inform job seekers about Arvinas Inc.. The employee data is based on information from people who have self-reported their past or current employments at Arvinas Inc.. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Arvinas Inc.. The data presented on this page does not represent the view of Arvinas Inc. and its employees or that of Zippia.
Arvinas Inc. may also be known as or be related to ARVINAS, INC., Arvinas, Arvinas Inc, Arvinas Inc. and Arvinas, Inc.